Is NCT06067269 recruiting in Los Angeles, CA?

Yes, NCT06067269 is currently recruiting participants at its Los Angeles, CA location. This prostate adenocarcinoma clinical trial is actively enrolling qualified participants.

How do I join the prostate adenocarcinoma clinical trial in Los Angeles?

To join this clinical trial in Los Angeles, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Los Angeles clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Prostate Adenocarcinoma Clinical Trial in Los Angeles, CA

About This Prostate Adenocarcinoma Study in Los Angeles

This phase II trial evaluates apalutamide in combination with image-guided stereotactic body radiation therapy (SBRT) for the treatment of patients with prostate cancer. Prostate cancer usually needs the hormone testosterone to grow. Apalutamide is a hormone therapy that blocks the effect of testosterone on prostate tumor cells. This may help stop the growth of tumor cells that need testosterone to grow. Image-guided SBRT is a standard treatment for some types of prostate cancer. This treatment combines imaging of cancer within the body, with the delivery of therapeutic radiation doses produced on a linear accelerator machine. SBRT uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Combining apalutamide with image-guided SBRT may increase a prostate cancer patient's chances of achieving an extremely low prostate specific antigen response, which is an early predictor of disease cure.

Sponsor: Jonsson Comprehensive Cancer Center

Who Can Participate

Inclusion Criteria

Confirmed diagnosis of prostate adenocarcinoma

Classified as having National Comprehensive Cancer Network unfavorable intermediate risk prostate cancer (i.e., \[a\] 2 of the following: PSA 10-20 ng/mL, clinical T category 2b-2c, or International Society of Urological Pathology \[ISUP\] grade group 2; \[b\] OR any 1 of \[a\] with ISUP grade group 3 disease; OR \[c\] any 1 of \[a\] with 50% or more cores on systematic biopsy showing prostate cancer)

Have a Decipher genomic classifier score

Have at least one dominant intraprostatic lesion visible on multiparametric MRI (Prostate Imaging-Reporting and Data System \[PI-RADS\] version 2.1 score 4 or 5)

Have underwent a prostate specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT)

Have total testosterone \>= 150 ng/dL

Adequate performance status (Eastern Cooperative Oncology Group \[ECOG\] 0-1)

Hemoglobin ≥ 9.0 g/dL, independent of transfusion and/or growth factors within 3 months prior to randomization (at screening)

Platelet count ≥ 100,000 x 10\^9/uL independent of transfusion and/or growth factors within 3 months prior to randomization (at screening)

Serum albumin ≥ 3.0 g/dL (at screening)

Glomerular filtration rate (GFR) ≥ 45 mL/min (at screening)

Serum potassium ≥ 3.5 mmol/L (at screening)

Serum total bilirubin ≤ 1.5 x upper limit of normal (ULN) (Note: In subjects with Gilbert's syndrome, if total bilirubin is \> 1.5 x ULN, measure direct and indirect bilirubin and if direct bilirubin is ≤ 1.5 x ULN, subject may be eligible) (at screening)

Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \< 2.5 x ULN (at screening)

Medications known to lower the seizure threshold (see list under prohibited medications) must be discontinued or substituted at least 4 weeks prior to study entry

Exclusion Criteria

Any evidence of spinal cord compression (radiological or clinical)

Prior pelvic malignancy

Prior pelvic radiation

Concurrent malignancy other than adequately treated basal cell or squamous cell skin cancer, non-muscle invasive bladder cancer (NMIBC), or any other cancer in situ currently without evidence of recurrence or progression

Inability to undergo radiotherapy, or hormonal therapy

Primary small cell carcinoma of the prostate (prostate adenocarcinoma with neuroendocrine differentiation is allowed)

Inflammatory bowel disease or active collagen vascular disease

History of any of the following:

Seizure or known condition that may pre-dispose to seizure (e.g. prior stroke within 1 year to randomization, brain arteriovenous malformation, Schwannoma, meningioma, or other benign central nervous system \[CNS\] or meningeal disease which may require treatment with surgery or radiation therapy)

Severe or unstable angina, myocardial infarction, symptomatic congestive heart failure, arterial or venous thromboembolic events (eg, pulmonary embolism, cerebrovascular accident including transient ischemic attacks), or clinically significant ventricular arrhythmias within 6 months prior to randomization

Current evidence of any of the following:

Uncontrolled hypertension

Gastrointestinal disorder affecting absorption

Known active infection (eg, human immunodeficiency virus \[HIV\] or viral hepatitis)

Any condition that in the opinion of the investigator would preclude participation in this study

Treatment with CYP2D6 substrates that have a narrow therapeutic index. If an alternative treatment cannot be used, a dose reduction of the CYP2D6 substrate may be considered

Baseline moderate and severe hepatic impairment (Child Pugh class B \& C)

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Los Angeles?

Yes, this clinical trial (NCT06067269) has an active research site in Los Angeles, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Prostate Adenocarcinoma Treatment Options in Los Angeles, CA

If you're searching for prostate adenocarcinoma treatment options in Los Angeles, CA, this clinical trial (NCT06067269) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Los Angeles research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced prostate adenocarcinoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all prostate adenocarcinoma clinical trials near you to find additional studies recruiting in your area.

Prostate Adenocarcinoma Clinical Trial in Los Angeles, CA

Expert Care in Los Angeles

IRB Approved

No-Cost Care

Apply for This Los Angeles Location

Why Participate?

Simple Process